Loading
A phase 1/2 trial of JNJ-90014496 in non-hodgkin lymphoma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05421663 by Janssen Research & Development, LLC, with 166 participants enrolled, started 2022-08-12 and due to reach its primary completion in 2041-07-30. Interventions recorded: JNJ-90014496. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/